ReviewInternational journal of molecular and cellular medicine2014
Hepatitis C virus and vaccine development.
Review in International journal of molecular and cellular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia.Vaccines · 2020Article
- Twitter As a Noninvasive Bio-Marker for Trends in Liver Disease.Hepatology communications · 2019Article
- Review
- T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.International review of cell and molecular biology · 2019Review
- Development of Preventive Vaccines for Hepatitis C Virus E1/E2 Protein.Iranian journal of pathology · 2018Review
- Global elimination of hepatitis C virus infection: Progresses and the remaining challenges.World journal of hepatology · 2017Review
- Tackling the Hepatitis C Disease Burden in Punjab, India.Journal of clinical and experimental hepatology · 2016Review
- Viral hepatitis: Indian scenario.Medical journal, Armed Forces India · 2016Article
- Combating the wrath of viral hepatitis in India.The Indian journal of medical research · 2016Article
- Status of hepatitis C virus vaccination: Recent update.World journal of gastroenterology · 2016Review
- Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C.Current therapeutic research, clinical and experimentalArticle
- Hepatitis C virus core protein: Not just a nucleocapsid building block, but an immunity and inflammation modulator.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical use. DNA vaccines have some advantages such as producing feasibility and generating intensive cellular and humoral immune responses. Activation and improvement of natural immune defense mechanisms is a necessity for the development of an effective HCV vaccine. This article discusses the current status of therapies for hepatitis C, the promising new therapies and the experimental strategies to develop an HCV vaccine.
Indexed as
Identifiers
25635247PMC4293608W2169998314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.